These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 12827262

  • 1. [Detection of prostate carcinomas with T1-weighted dynamic contrast-enhanced MRI. Value of two-compartment model].
    Kiessling F, Lichy M, Grobholz R, Farhan N, Heilmann M, Michel MS, Trojan L, Werner A, Rabe J, Delorme S, Kauczor HU, Schlemmer HP.
    Radiologe; 2003 Jun; 43(6):474-80. PubMed ID: 12827262
    [Abstract] [Full Text] [Related]

  • 2. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M, Zelhof B, Liney GP, Gibbs P, Pickles MD, Turnbull LW.
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [Abstract] [Full Text] [Related]

  • 3. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O, Lüdemann L, Prochnow D, Abramjuk C, Taupitz M, Hamm B, Beyersdorff D.
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M.
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [Abstract] [Full Text] [Related]

  • 5. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
    Cornud F, Beuvon F, Thévenin F, Chauveinc L, Vieillefond A, Descazeaux A, Flam T.
    Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
    [Abstract] [Full Text] [Related]

  • 6. [Hemodynamic and metabolic characterization of orthotopic rat prostate carcinomas using dynamic MRI and proton magnetic resonance spectroscopy].
    Kiessling F, Lichy M, Grobholz R, Heilmann M, Huber PE, Meding J, Peschke P, Kauczor HU, Schlemmer HP.
    Radiologe; 2003 Jun; 43(6):489-94. PubMed ID: 12827264
    [Abstract] [Full Text] [Related]

  • 7. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI.
    Kershaw LE, Hutchinson CE, Buckley DL.
    J Magn Reson Imaging; 2009 Mar; 29(3):641-8. PubMed ID: 19243046
    [Abstract] [Full Text] [Related]

  • 8. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL.
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [Abstract] [Full Text] [Related]

  • 9. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
    van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, de la Rosette JJ, Barentsz JO, Heerschap A.
    J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
    [Abstract] [Full Text] [Related]

  • 10. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.
    Ren J, Huan Y, Wang H, Chang YJ, Zhao HT, Ge YL, Liu Y, Yang Y.
    Clin Radiol; 2008 Feb; 63(2):153-9. PubMed ID: 18194690
    [Abstract] [Full Text] [Related]

  • 11. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
    Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM.
    AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T, Lüdemann L, Rudolph B, Rehbein H, Staack A, Taupitz M, Prochnow D, Beyersdorff D.
    Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
    [Abstract] [Full Text] [Related]

  • 13. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.
    Riches SF, Payne GS, Morgan VA, Sandhu S, Fisher C, Germuska M, Collins DJ, Thompson A, deSouza NM.
    AJR Am J Roentgenol; 2009 Dec; 193(6):1583-91. PubMed ID: 19933651
    [Abstract] [Full Text] [Related]

  • 14. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):425-30. PubMed ID: 17881141
    [Abstract] [Full Text] [Related]

  • 15. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology.
    Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL.
    J Magn Reson Imaging; 2006 Jul 01; 24(1):108-13. PubMed ID: 16767709
    [Abstract] [Full Text] [Related]

  • 16. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
    Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L.
    J Urol; 2006 Dec 01; 176(6 Pt 1):2432-7. PubMed ID: 17085122
    [Abstract] [Full Text] [Related]

  • 17. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.
    Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO.
    Radiology; 2003 Oct 01; 229(1):248-54. PubMed ID: 12944607
    [Abstract] [Full Text] [Related]

  • 18. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
    Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S.
    J Magn Reson Imaging; 2007 Jan 01; 25(1):146-52. PubMed ID: 17139633
    [Abstract] [Full Text] [Related]

  • 19. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?
    Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G.
    Eur Radiol; 2004 Feb 01; 14(2):309-17. PubMed ID: 14531000
    [Abstract] [Full Text] [Related]

  • 20. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.
    Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS.
    J Magn Reson Imaging; 2005 Nov 01; 22(5):639-46. PubMed ID: 16200542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.